证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|----------------------------------|-------------------|--------------------------------------------------------|-------|-------|-------|----------| | | | | | | | | | | | □特定对象调研 □分析师会议 | | | | | | | | 投资者关系活动 | □媒体采访 | ☑ 业绩说明会 | | | | | | | 类别 | □新闻发布会 | □路演活动 | | | | | | | | □现场参观 | | | | | | | | | ☑ 其他 （ 2022 | | 年上海辖区上市公司集体接待日暨中报业绩说 | | | | | | | 明会活动） | | | | | | | | 参与单 ...

编号：2022-001 ☑特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他 证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 参与单位名称及 | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | | | | | 人员姓名 | 宝盈基金－张若伦 | | | 时间 | 2022 年 9 月 7 日（周三）下午 13:30-14:30 | | | 地点 | 通讯会议 | | | 上市公司接待人 员姓名 | 董事长兼总经理：洪伟 董事会秘书：张维娓 | | | | 财务总监：周茜 保持同步增长趋势？ ...

Financial Performance - Revenue for Q3 2022 was CNY 119,423,568.98, a decrease of 16.14% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 12,829,751.80, down 23.97% year-on-year[5] - Basic earnings per share for Q3 2022 was CNY 0.1604, a decline of 42.98% compared to the previous year[5] - Total operating revenue for Q3 2022 was CNY 316,598,072.90, a decrease of 18.8% compared to CNY 389,974,313.07 in the same period last year[19] - Net profit for Q3 2022 was CNY 36,591,811.86, representing a decline of 32.5% from CNY 54,206,098.58 in Q3 2021[19] - Earnings per share for Q3 2022 were CNY 0.5489, compared to CNY 0.9034 in the previous year, reflecting a decrease of 39.2%[20] Assets and Equity - Total assets at the end of Q3 2022 reached CNY 841,726,644.37, an increase of 58.91% from the end of the previous year[5] - Shareholders' equity attributable to the parent company was CNY 765,759,541.60, up 136.24% year-on-year[5] - The company's total liabilities decreased to CNY 75,967,102.77 from CNY 205,543,585.50, a reduction of 63.1% year-over-year[19] - The total equity attributable to shareholders increased to CNY 765,759,541.60 from CNY 324,148,372.84, an increase of 136.3%[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 26,354,840.08, down 14.05% compared to the previous year[5] - The net cash flow from operating activities for the current period is CNY 26,354,840.08, a decrease of 13.5% compared to CNY 30,663,156.56 in the previous period[22] - Total cash inflow from investment activities is CNY 301,666,987.42, significantly higher than CNY 58,055,379.20 in the previous period[22] - Cash inflow from financing activities amounts to CNY 446,938,473.00, compared to CNY 81,604,661.41 in the previous period, indicating a substantial increase[22] - The net cash flow from financing activities is CNY 292,691,432.97, up from CNY 76,885,519.80 in the previous period[22] Investment and Expenses - The company reported a significant increase in cash and cash equivalents, rising by 186.81% to CNY 346,770,699.58[9] - The company’s capital reserve increased by 903.69% to CNY 427,624,413.30 due to the initial public offering[9] - Research and development expenses for Q3 2022 were CNY 13,557,753.52, down 25.5% from CNY 18,135,558.29 in the same quarter last year[19] - The company experienced a 71.56% decrease in other income, totaling CNY 1,461,099.00, primarily due to changes in government subsidies[10] Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue growth[19]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥197,174,503.92, a decrease of 20.36% compared to ¥247,573,993.13 in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was ¥23,762,060.06, down 36.35% from ¥37,331,756.08 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥22,629,650.77, a decrease of 28.53% compared to ¥31,662,065.42 in the same period last year[22]. - The basic earnings per share for the first half of 2022 was ¥0.3960, down 36.35% from ¥0.6222 in the same period last year[22]. - The weighted average return on equity decreased to 7.07% from 13.71% in the previous year[22]. - The gross profit margin for functional feed additives was 28.42%, down 5.50% year-on-year, while the gross profit margin for nutritional feed additives was 29.43%, down 3.60% year-on-year[44]. - The company reported a significant increase in cash generated from financing activities, amounting to ¥425,725,625.47, a 512.97% increase from ¥69,452,879.64, primarily due to new share issuance[42]. - The company reported a total of ¥40,503.31 million raised from its initial public offering, with a net amount of ¥40,503.31 million after deducting issuance costs[60]. - The company plans to set a performance guidance of 2 billion in revenue for the full year 2022, indicating strong growth potential[125]. Assets and Liabilities - The company's total assets increased by 81.61% to ¥961,960,752.61 from ¥529,691,958.34 at the end of the previous year[22]. - The net assets attributable to shareholders rose by 132.28% to ¥752,929,789.80 from ¥324,148,372.84 at the end of the previous year[22]. - The proportion of monetary funds increased to 54.23% of total assets, up from 22.83% at the end of the previous year, primarily due to the influx of raised funds[48]. - The company's total liabilities decreased by ¥272,881.37 during the reporting period[51]. - The company's total liabilities amounted to CNY 209,030,962.81, slightly up from CNY 205,543,585.50, indicating a marginal increase of about 0.7%[159]. Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥1,419,229.58 compared to a net outflow of ¥10,471,565.40 in the same period last year, representing an improvement of 86.45%[22]. - Cash and cash equivalents increased to ¥402,445,828.18, a remarkable increase of 2,783.68% from a negative balance of ¥14,931,881.43 in the previous year[42]. - The company's cash flow from operating activities improved significantly, with a net cash flow of -¥1,419,229.58, an 86.45% improvement from -¥10,471,565.40 in the previous year[42]. - The company reported a net increase in cash and cash equivalents of 402,445,828.18 CNY for the first half of 2022, contrasting with a decrease of 14,931,881.43 CNY in the first half of 2021[172]. Research and Development - The company focuses on the research, production, and sales of feed additives and enzymatic protein feed materials, emphasizing a "technology-driven value" approach with a strong R&D team[30]. - Research and development expenses were ¥6,901,676.30, down 40.41% from ¥11,582,379.92, mainly due to reduced experimental activities caused by the pandemic[42]. - The company has established a stable and professional talent pool, with 42.1% of employees holding a master's degree or higher as of June 2022[33]. - As of June 2022, the company holds 28 invention patents and 11 utility model patents, showcasing its commitment to independent innovation in the feed additive industry[34]. - The company has allocated CNY 19.24 million for research and development in the first half of 2022, which is a strategic focus for enhancing product offerings[183]. Market and Competition - The company faces risks including market competition, raw material price fluctuations, and cyclical volatility in the pig farming industry[3]. - The demand for feed additives is expected to increase as large-scale farming operations prioritize animal production efficiency, with a notable shift towards "green, efficient, and safe" products[31]. - The company is expanding its product offerings to include additives for ruminants, poultry, and aquaculture to reduce reliance on the pig farming sector[76]. - The company is closely monitoring changes in foreign market environments, including political and economic factors, to manage risks associated with international sales[79]. - The company plans to invest in research and development to enhance its competitive edge and reduce the impact of market competition[74]. Environmental and Compliance - The company transitioned its heat source fuel from coal to natural gas at the beginning of 2022, meeting relevant emission standards as verified by the environmental protection bureau[91]. - The company has implemented a waste storage area with proper safety measures and signage for hazardous waste, ensuring compliance with regulations[92]. - The company conducts regular self-monitoring of emissions, with a third-party monitoring agency responsible for quality assurance and control[93]. - The company has no significant legal disputes or administrative penalties related to environmental issues during the reporting period[104]. Corporate Governance - The company maintains a governance structure that ensures clear responsibilities and effective checks and balances, enhancing decision-making and risk management[98]. - The company actively engages in investor relations, ensuring transparency and compliance with relevant laws and regulations[99]. - The financial report for the first half of 2022 was not audited, which may impact the reliability of the financial data presented[155]. Subsidiaries and Acquisitions - The company’s subsidiary, Suzhou Meinong, reported a net profit of 422,950.3 yuan, contributing significantly to the overall performance[72]. - The company’s subsidiary, Chengdu Meiyi, generated a net profit of 4,191,464 yuan, indicating strong operational performance[72]. - A strategic acquisition was completed in May 2022, which is expected to contribute an additional 370.47 million in annual revenue[125]. - The company has a total of 100% ownership in two subsidiaries: Chengdu Meiyide Biotechnology Co., Ltd. and Suzhou Meino Biological Technology Co., Ltd.[190]. Future Outlook - The company provided a future outlook projecting continued revenue growth, with an estimated increase of 15% year-over-year for the next fiscal year[125]. - The management provided a positive outlook for the second half of 2022, expecting a recovery in sales and profitability[180]. - The company aims to increase its market share by 10% in the upcoming fiscal year through strategic marketing initiatives[180].